BioArctic AB (publ)

LSE:0RV2 Stock Report

Market Cap: SEK 19.8b

BioArctic Valuation

Is 0RV2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RV2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 36.77
Fair Value
516.8% overvalued intrinsic discount
5
Number of Analysts

Below Fair Value: 0RV2 (SEK226.79) is trading above our estimate of fair value (SEK36.77)

Significantly Below Fair Value: 0RV2 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RV2?

Key metric: As 0RV2 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0RV2. This is calculated by dividing 0RV2's market cap by their current book value.
What is 0RV2's PB Ratio?
PB Ratio21.5x
BookSEK 918.63m
Market CapSEK 19.78b

Price to Book Ratio vs Peers

How does 0RV2's PB Ratio compare to its peers?

The above table shows the PB ratio for 0RV2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.3x
GNS Genus
2.1x37.2%UK£1.2b
AVCT Avacta Group
3.5x-2.1%UK£170.1m
OXB Oxford Biomedica
6.4x92.5%UK£423.4m
BVXP Bioventix
13.1xn/aUK£157.6m
0RV2 BioArctic
21.5x49.7%SEK 19.8b

Price-To-Book vs Peers: 0RV2 is expensive based on its Price-To-Book Ratio (21.5x) compared to the peer average (6.3x).

Price to Book Ratio vs Industry

How does 0RV2's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
VAL ValiRx
0.2xn/aUS$1.11m
LLAI LungLife AI
0.1x101.0%US$759.90k
0HMP Bellerophon Therapeutics
0.1xn/aUS$489.31k
No more companies available in this PB range
0RV2 21.5xIndustry Avg. 3.1xNo. of Companies4PB01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0RV2 is expensive based on its Price-To-Book Ratio (21.5x) compared to the UK Biotechs industry average (3.1x).

Price to Book Ratio vs Fair Ratio

What is 0RV2's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RV2 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio21.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0RV2's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RV2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 226.79
SEK 326.80
+44.1%
4.7%SEK 350.00SEK 310.00n/a5
Feb ’26SEK 220.87
SEK 326.80
+48.0%
4.7%SEK 350.00SEK 310.00n/a5
Jan ’26SEK 201.11
SEK 322.00
+60.1%
6.5%SEK 350.00SEK 292.00n/a5
Dec ’25SEK 191.60
SEK 322.00
+68.1%
6.5%SEK 350.00SEK 292.00n/a5
Nov ’25SEK 144.44
SEK 292.20
+102.3%
8.5%SEK 340.00SEK 270.00n/a5
Oct ’25SEK 157.90
SEK 290.60
+84.0%
8.8%SEK 340.00SEK 270.00n/a5
Sep ’25SEK 171.08
SEK 290.60
+69.9%
8.8%SEK 340.00SEK 270.00n/a5
Aug ’25SEK 159.10
SEK 336.40
+111.4%
8.1%SEK 370.00SEK 290.00n/a5
Jul ’25SEK 232.79
SEK 368.00
+58.1%
11.8%SEK 450.00SEK 325.00n/a5
Jun ’25SEK 240.81
SEK 368.00
+52.8%
11.8%SEK 450.00SEK 325.00n/a5
May ’25SEK 194.30
SEK 366.20
+88.5%
12.2%SEK 450.00SEK 325.00n/a5
Apr ’25SEK 213.10
SEK 366.20
+71.8%
12.2%SEK 450.00SEK 325.00n/a5
Mar ’25SEK 217.63
SEK 365.20
+67.8%
12.2%SEK 450.00SEK 325.00n/a5
Feb ’25SEK 216.24
SEK 376.40
+74.1%
8.8%SEK 440.00SEK 342.00SEK 220.875
Jan ’25SEK 275.60
SEK 369.33
+34.0%
11.1%SEK 450.00SEK 312.00SEK 201.116
Dec ’24SEK 231.03
SEK 372.40
+61.2%
11.9%SEK 450.00SEK 312.00SEK 191.605
Nov ’24SEK 220.46
SEK 392.00
+77.8%
8.8%SEK 450.00SEK 356.00SEK 144.445
Oct ’24SEK 281.20
SEK 392.00
+39.4%
8.8%SEK 450.00SEK 356.00SEK 157.905
Sep ’24SEK 312.20
SEK 392.00
+25.6%
8.8%SEK 450.00SEK 356.00SEK 171.085
Aug ’24SEK 298.80
SEK 392.00
+31.2%
8.8%SEK 450.00SEK 356.00SEK 159.105
Jul ’24SEK 282.00
SEK 395.20
+40.1%
10.6%SEK 460.00SEK 356.00SEK 232.795
Jun ’24SEK 326.20
SEK 395.20
+21.2%
10.6%SEK 460.00SEK 356.00SEK 240.815
May ’24SEK 264.71
SEK 395.20
+49.3%
10.6%SEK 460.00SEK 356.00SEK 194.305
Apr ’24SEK 252.89
SEK 399.20
+57.9%
9.9%SEK 460.00SEK 356.00SEK 213.105
Mar ’24SEK 295.39
SEK 399.20
+35.1%
9.9%SEK 460.00SEK 356.00SEK 217.635
Feb ’24SEK 311.39
SEK 367.80
+18.1%
22.5%SEK 460.00SEK 220.00SEK 216.245
Analyst Price Target
Consensus Narrative from 5 Analysts
SEK 331.17
Fair Value
31.5% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 03:16
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioArctic AB (publ) is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Patrik LingDNB Markets
Rajan SharmaGoldman Sachs